Efficacy of mesenchymal stem cell transplantation therapy for type 1 and type 2 diabetes mellitus: a meta-analysis

Table 5 Insulin requirements of patients with T2DM at 3, 6, and 12 months after MSC therapy

Follow-up (months)	Test for heterogeneity		Analysis model	Test for overall effect		WMD or SMD	95% CI
Follow-up (months)	I² (%)	P	Analysis model	Z	P	WMD or SMD	95% CI
3	0	0.94	Fixed	3.4	0.0007	−0.89	(−1.40, −0.38)
6	0	0.56	Fixed	5.46	<0.00001	−1.22	(−1.66, −0.78)
12	0	0.53	Fixed	3.96	<0.0001	−1.07	(−1.60, −0.54)

Abbreviations: T2DM type 2 diabetes, MSCs mesenchymal stem cells, WMD weighted mean difference, SMD standard mean difference

ISSN: 1757-6512